A new patient to our HMO has been prescribed Xolair (Omalizumab) injections. She told us that her previous provider allowed her to administer the biologic at home. This is not our policy. We are wondering if this is accepted practice elsewhere, and if so how widespread is it?
Because of the small risk of anaphylactic reactions, 0.1-0.2%, and the need to reconstitute the omalizumab, home administration is not accepted practice.
Dr. Jacqueline A. Pongracic, FAAAAI